Home › Companies › MAIA

Pipeline (7 active programs)

Capital (as filed)

Cash

$0K cash and cash equivalents · Jun 30, 2026 (10-Q)

Operating cash flow

−$6.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$27.6M cash per the update of Oct 7, 2026 — the company's own words as read there, not the filed figure

Offering documents (5)

• 2026-10-07 424B3 · Resale (selling stockholders)
• 2026-10-02 424B3 · Resale (selling stockholders)
• 2026-09-25 S-3 · Shelf registration
• 2026-08-21 S-3 · Shelf registration up to $150M aggregate
• 2026-05-14 424B5 · At-the-market program up to $11.2M

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

• 2026-10-08 UPDATE: MAIA Biotechnology (MAIA) - Part C Is Closed, the Phase 3 Hits 65 🔒 Paid
• 2026-08-11 UPDATE: MAIA Biotechnology (MAIA) - The Burn Rate Catches Up 🔒 Paid
• 2026-07-08 UPDATE: MAIA Biotechnology (MAIA) - Part C Delivers a 90.5% Disease Control Rate 🔒 Paid
• 2026-06-25 UPDATE: MAIA Biotechnology (MAIA) - International Part C Enrollment Is Done 🔒 Paid
• 2026-06-04 UPDATE: MAIA Biotechnology (MAIA) - The Phase 3 Number, and the Interim Slips to 2027
• 2026-06-03 UPDATE: MAIA Biotechnology (MAIA) - The U.S. Door Opens for the Accelerated Approval Cohort
• 2026-06-02 UPDATE: MAIA Biotechnology (MAIA) - The CEO Doubles Down, and a Director Joins Him
• 2026-05-15 UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final 🔒 Paid
• 2026-05-12 UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces
• 2026-03-30 Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on MAIA Biotechnology, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-03-30 Speculative buy speculative Maia Biotechnology (MAIA) - Scientific Deep Dive for Ateganosine and Pipeline Products The mechanism is chemically elegant and the Phase 2 survival data in 3L NSCLC is compelling, but near-term dilution and method-of-use patent risks require a speculative position sizing.
2. 2026-05-12 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Banker Lawsuit Lands and a Bitcoin Plan Surfaces Clinical thesis intact with U.S. site activation and eight 2-year survivors, dilution gap closed, but the crypto treasury plan and now-docketed Wainwright lawsuit add governance risk requiring eyes-open positioning.
3. 2026-05-15 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Wainwright Divorce Is Final ATM termination removes a dilution lever and is the right governance call, but the crypto plan and Wainwright lawsuit remain unresolved; clinical thesis is unchanged.
4. 2026-06-02 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The CEO Doubles Down, and a Director Joins Him CEO's second open-market buy in six months joined by a director is an incrementally bullish insider signal, but governance rakes remain unmoved and the data is not yet worth a re-rating.
5. 2026-06-03 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The U.S. Door Opens for the Accelerated Approval Cohort FDA IND clearance enabling U.S. enrollment in the THIO-101 Parts C/D Accelerated Approval cohort is an incremental operational positive, but governance overhang is unchanged and the Phase 3 interim remains the main event.
6. 2026-06-04 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Phase 3 Number, and the Interim Slips to 2027 First hard Phase 3 enrollment number (29 patients) is credible progress, but the interim analysis has formally slipped to 2027, extending the holding period; Parts C/D ORR is now the closer catalyst.
7. 2026-06-25 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - International Part C Enrollment Is Done International Part C enrollment closing with U.S. sites ramping is incrementally positive for the Accelerated Approval pathway, though the ORR readout remains ahead and governance overhang is unchanged.
8. 2026-07-08 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Delivers a 90.5% Disease Control Rate A 90.5% DCR in Part C's harder-to-treat population tracks the Parts A/B signal and retires the small-N reversion bear case, but the ORR number needed for Accelerated Approval filing is still outstanding.
9. 2026-08-11 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - The Burn Rate Catches Up Clinical thesis remains intact but burn rate stepped up to ~$6.8M/quarter, thinning the runway cushion, and the crypto treasury plan surviving a second 10-Q without rescission is a meaningful governance black mark.
10. 2026-10-08 Speculative buy speculative UPDATE: MAIA Biotechnology (MAIA) - Part C Is Closed, the Phase 3 Hits 65 Part C enrollment complete and THIO-104 at 65 patients is real clinical progress, but a $1M stock-for-funding deal signals the 'fully funded' framing has worn thin and the ORR number remains the key re-rating catalyst.

• Long call · opened Mar 30, 2026 at $1.31 · -19.1% vs XBI +28.1% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (40)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Mar 31, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Oct 7, 2026ReleaseMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer→ BD updateSummary on the 424B3BD extracted 1 program update from this document → MAIA pipeline
• Oct 7, 2026424B3Prospectus (resale / update)→ BD updateMAIA closes Part C enrollment and prints a 65-patient Phase 3 count — the two enrollment watch items from the August update in one release — while a quiet Clinical Trial Funding Agreement with PoC Capital surfaces a new $1M non-dilutive (ish) financing structure the tape hasn't fully priced.
• Oct 6, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Oct 2, 2026424B3Prospectus (resale / update)MAIA quietly struck a Clinical Trial Funding Agreement with PoC Capital, LLC on August 29, exchanging 751,879 shares for $1M in trial funding — the first concrete "Tranche 2"-style structured deal to surface, and a new freely tradable equity overhang filed after today's close.
• Sep 25, 2026S-3Shelf registrationMAIA quietly filed an S-3 after today's close registering 751,879 shares issued to PoC Capital LLC under an August 29 Clinical Trial Funding Agreement — trading a small equity stake for $1M in trial funding, a non-dilutive structure that signals management is bridging the tightening runway without a marketed offering.
• Sep 23, 2026ReleaseMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
• Sep 22, 2026ReleaseMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung CancerBD extracted 1 program update from this document → MAIA pipeline
• Sep 16, 2026ReleaseMAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical TrialThe first U.S. patient has been dosed in THIO-101 Parts C/D — the cohort anchoring MAIA's Accelerated Approval pathway — funded by a $2.3M NIH grant, closing a key operational gap I've been tracking since the Phase 3 interim slipped to 2027.
• Sep 15, 2026ReleaseMAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEOA board member and the CEO stepped back into the open market — $352K combined, D&O ownership now at 21.34% — signaling insider conviction ahead of the Part C ORR readout and the tightening runway flagged last month.
• Sep 10, 2026ReleaseMAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
• Aug 21, 2026S-3Shelf registration
• Aug 10, 202610-QQuarterly report
• Jul 8, 2026ReleaseMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialBD extracted 1 program update from this document → MAIA pipeline
• Jun 25, 2026ReleaseMAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
• Jun 18, 2026ReleaseMAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
• Jun 10, 2026ReleaseMAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
• Jun 4, 2026ReleaseMAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
• Jun 3, 2026ReleaseMAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial ExpansionBD extracted 2 program updates from this document → MAIA pipeline
• Jun 2, 2026ReleaseMAIA Biotechnology Announces Open Market Purchases by CEO and Director
• Jun 1, 2026ReleaseMAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical OncologyBD extracted 1 program update from this document → MAIA pipeline
• May 22, 20268-KCurrent report: shareholder vote
• May 19, 2026DEFA14AProxy soliciting material
• May 14, 20268-KCurrent report: agreement terminated
• May 14, 2026424B5Prospectus supplement (offering)
• May 11, 202610-QQuarterly report
• Apr 27, 2026DEFA14AProxy soliciting material
• Apr 16, 2026ReleaseMAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
• Apr 16, 20268-KCurrent report: other events · EX-99.1
• Apr 8, 2026ReleaseMAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
• Apr 8, 20268-KCurrent report: other events · EX-99.1
• Apr 7, 2026DEFA14AProxy soliciting material
• Apr 7, 2026DEF 14AProxy statement
• Apr 2, 20268-KCurrent report: officer / director change
• Mar 31, 2026ReleaseMAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
• Mar 31, 20268-KCurrent report: other events · EX-99.1
• Mar 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
• Mar 23, 202610-KAnnual report
• Mar 4, 20268-KCurrent report: material agreement, other events · EX-99.1
• Mar 4, 2026424B5Prospectus supplement (offering)
• Mar 2, 2026424B5Prospectus supplement (offering)